TD Cowen Reiterates Buy Rating on Adverum Biotechnologies (ADVM)

TD Cowen analyst Joseph Thome reiterated a Buy rating on Adverum Biotechnologies (NASDAQ: ADVM).

The analyst commented, "ADVM reported 26-wk data from the Ph. II LUNA study at ASRS, which continued to show strong efficacy for ixo-vec in wet AMD, along with good inflammation control particularly at the lower go-forward dose. ADVM next plans to show 9-mo data from LUNA in Q4, and remains on track to initiate a Ph. III program in H1:25. Add'l data will continue to refine profile. Remain Buy."

For an analyst ratings summary and ratings history on Adverum Biotechnologies click here. For more ratings news on Adverum Biotechnologies click here.

Shares of Adverum Biotechnologies closed at $8.92 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Full Circle Lithium closes $5.14M private placement
• Critical One Energy closes second tranche of flow-through placement